Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Colorectal Cancer RECHALLENGE

This study has been withdrawn prior to enrollment.
Sponsor:
Information provided by:
Sanofi
ClinicalTrials.gov Identifier:
NCT00988897
First received: September 28, 2009
Last updated: December 21, 2009
Last verified: December 2009

September 28, 2009
December 21, 2009
October 2009
May 2012   (final data collection date for primary outcome measure)
Primary endpoint for the first thirteen patients according to the Simons Design: Clinical DCR (Disease Control Rate) at the end of stage I, based on Response Evaluation Criteria on Solid Tumors (RECIST) criteria. [ Time Frame: At the end of 8 cycles or end of treatment which occurs first. ] [ Designated as safety issue: No ]
Same as current
Complete list of historical versions of study NCT00988897 on ClinicalTrials.gov Archive Site
  • Progression-free survival (PFS) [ Time Frame: evaluated at 10 weeks, 16 weeks and 40 weeks ] [ Designated as safety issue: No ]
  • Duration of response [ Time Frame: evaluated at 10 weeks, 16 weeks and 40 weeks ] [ Designated as safety issue: No ]
  • Adverse events [ Time Frame: At each visit, i.e. every two weeks ] [ Designated as safety issue: No ]
  • Overall response rate of stage I and II [ Time Frame: evaluated at week 14 ]
Same as current
Not Provided
Not Provided
 
Colorectal Cancer RECHALLENGE
A Phase II Study of Modified FOLFOX-6 Chemotherapy as First-line Treatment of Metastatic Colorectal Cancer in Patients Who Have Received Oxaliplatin-based Adjuvant Chemotherapy

Primary Objective:

  • To demonstrate that re-challenge with an oxaliplatin based regimen (modified FOLFOX-6) will provide a clinical disease control rate (DCR) of at least 20% at the end of the chemotherapy.

Secondary Objective:

  • To evaluate other measures of tumour's responses and safety.
Not Provided
Interventional
Phase 2
Allocation: Non-Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Colorectal Neoplasms
  • Drug: OXALIPLATIN (SR96669)
    Pharmaceutical form: Lyophilized powder for injection (50mg/vial or 100mg/vial) or aqueous solution (50mg/10mL or 100mg/20mL) Route of administration: IV
  • Drug: 5-FLUOROURACIL (5-FU)
    Pharmaceutical form: vials of 5g/100mL (50mg/mL) Route of administration: IV
  • Drug: LEUCOVORIN (LV)
    Pharmaceutical form: vials of 50mg/5mL or 500mg/50mL (10mg/mL) Route of administration: IV
  • Drug: BEVACIZUMAB
    Pharmaceutical form: vials of 100mg/4mL or 400mg/16mL (25mg/mL) Route of administration: IV
Experimental: 1

Patients will receive modified FOLFOX-6 regimen:

  • oxaliplatin 85mg/m2, day 1 (given as a 2-hour infusion)
  • LV 400mg/m2, day 1 (given as a 2-hour infusion simultaneous to oxaliplatin)
  • 5-FU given as a bolus IV 400mg/m2 dose on day 1 followed by 2400mg/m2 continuous infusion over 46 hours (day 1 and 2)

A cycle is defined as 2 weeks. Patients will receive cycles of modified FOLFOX-6 regimen every 2 weeks up to a maximum of 8 cycles. Use of bevacizumab is at the discretion of the treating physician.

Interventions:
  • Drug: OXALIPLATIN (SR96669)
  • Drug: 5-FLUOROURACIL (5-FU)
  • Drug: LEUCOVORIN (LV)
  • Drug: BEVACIZUMAB
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Withdrawn
0
May 2012
May 2012   (final data collection date for primary outcome measure)

Inclusion criteria:

  • Histologically proven adenocarcinoma of colon or rectum
  • Measurable metastatic disease, either inoperable, or residual after surgical procedure
  • No prior chemotherapy for metastatic disease
  • For colon cancer: prior adjuvant chemotherapy with oxaliplatin that ended at least 12 months prior to enrollment.
  • For rectal cancer: at least 12 months since prior use of oxaliplatin in neoadjuvant or adjuvant chemotherapy
  • Adequate liver and kidney function:

    • Total bilirubin inferior to 1.5 ULN
    • Serum Creatinine inferior to 150 umol/L
    • Creatinine clearance (ClCr) > 30 mL/min
    • ALT / AST inferior to 3 ULN
  • Adequate hematological function

    • Neutrophils > or equal 1.5 x 109/L
    • Platelets > or equal 100 x 109/L

Exclusion criteria:

  • Metastatic disease presenting without prior adjuvant chemotherapy
  • Metastatic disease presenting after non-oxaliplatin-containing adjuvant chemotherapy
  • Peripheral sensory or motor neuropathy > grade 1
  • Eastern Cooperative Oncology Group (ECOG) Performance status > 2
  • Other active malignancy
  • History of known allergy to oxaliplatin or other platinum compounds, to 5-FU, to Leucovorin or to any ingredients in the formulations or the containers
  • Patients who are pregnant, or breast-feeding
  • Patients with severe renal impairment (ClCr < 30 mL/min)
  • Pernicious anemia or other megaloblastic anemia with Vitamin B12 deficiency
  • Patients with reproductive potential not implementing accepted and effective method of contraception (the definition of effective method of contraception will be based on the investigators' judgment)
  • Participation in another clinical trial with any investigational drug within 30 days prior to study screening
  • For patient who will receive Bevacizumab: Bevacizumab is contraindicated in patients with know hypersensitivity to any components of the product and to Chinese hamster ovary cell product or other recombinant human or humanized antibodies
  • Presence of any symptoms suggesting brain metastasis

The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.

Both
18 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Canada
 
NCT00988897
OXALI_L_03943
Not Provided
Medical Affairs Study Director, sanofi-aventis
Sanofi
Not Provided
Study Director: Medical Affairs Sanofi
Sanofi
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP